← back to search

Pol Specenier

University of Antwerp · BE
Area of research
Otorhinolaryngology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, and Oral health in cancer treatment.
h-index
30
citations
5,009
works
168
NIH funding
primary concept
Medicine
email

Recent publications

Toxicities in long‐term survivors of head and neck cancer—A multi‐national cross‐sectional analysis
International Journal of Cancer 2025cited by 6position: middledoi
Long‐term health‐related quality of life in head and neck cancer survivors: A large multinational study
International Journal of Cancer 2024cited by 39position: middledoi
Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study
BMC Geriatrics 2022cited by 31position: middledoi
Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>Mutations
Journal of Clinical Oncology 2021cited by 194position: middledoi
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
European Journal of Cancer 2021cited by 54position: middledoi
Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium
Annals of Oncology 2018cited by 61position: middledoi
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
International Journal of Molecular Sciences 2017cited by 31position: middledoi
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Neuro-Oncology 2016cited by 270position: middledoi
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Cancer 2016cited by 45position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Santosh Kesari · Santa Monica College2 papers (2016–2017)Ann Cleverly · UCB Pharma (United Kingdom)2 papers (2016–2017)Helen Wheeler · University of Sydney2 papers (2016–2017)Philip R. Debruyne · AZ Groeninge2 papers (2021–2022)Olivier Chinot · Peuplements végétaux et bioagresseurs en milieu tropical2 papers (2016–2017)Joachim P. Steinbach · Goethe University Frankfurt2 papers (2016–2017)Alain Carpentier · Centre National de la Recherche Scientifique2 papers (2016–2017)Juan Manuel Sepúlveda-Sánchez · Research Institute Hospital 12 de Octubre2 papers (2016–2017)Wolfgang Wick · Heidelberger Institut für Radioonkologie2 papers (2016–2017)Alba A. Brandes · AstraZeneca (Italy)2 papers (2016–2017)Claire Smith · AstraZeneca (United Kingdom)2 papers (2016–2017)Susan C. Guba · Eli Lilly (United States)2 papers (2016–2017)Colin Miles · Eli Lilly (United Kingdom)2 papers (2016–2017)D. Desaiah · Eli Lilly (United States)2 papers (2016–2017)Ivelina Gueorguieva · Eli Lilly (United States)2 papers (2016–2017)Lawrence Cher · Austin Health2 papers (2016–2017)Jordi Rodón · University of California San Francisco Medical Center2 papers (2016–2017)Michael Lahn · University of Geneva2 papers (2016–2017)David Capper · German Cancer Research Center2 papers (2016–2017) · 1 papers (2017–2017)